New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For GOOG;EMC;VMW;INTC;GILD;FRX From The Last 14 Days
Check below for free stories on GOOG;EMC;VMW;INTC;GILD;FRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
July 25, 2014
16:02 EDTGOOGOptions Update; July 25, 2014
Subscribe for More Information
12:49 EDTGOOGYouTube could name music subscription service 'MusicKey,' GigaOM reports
Subscribe for More Information
08:47 EDTINTCMellanox points to bigger than expected Grantley ramp, says Janney Capital
Subscribe for More Information
07:47 EDTGOOGGoogle X project to gather 'baseline' of healthy human, WSJ says
Google X, the search giant's research arm, is undertaking "Baseline Study," an ambitious project to collect genetic and molecular information first from 175 people, and later from thousands more, to amass a much larger and broader set of new data on what a healthy human being should be than is currently available or being gathered by other mass studies, said The Wall Street Journal. Reference Link
07:25 EDTGILDGilead receives positive opinion from CHMP for Zydelig
Gilead Sciences announced that the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency, has adopted a positive opinion on the company’s Marketing Authorization Application for Zydelig, a first-in-class treatment for patients with chronic lymphocytic leukemia and follicular lymphoma, the most common subtype of indolent non-Hodgkin lymphoma. The CHMP opinion supports the use of Zydelig in combination with rituximab for the treatment of adult patients with CLL who have received at least one prior therapy or, as first-line treatment in CLL patients in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy and also as monotherapy for the treatment of adult patients with FL that is refractory to two prior lines of treatment. The CHMP’s recommendation will now be reviewed by the European Commission, which has the authority to approve medicines for use in the 28 countries of the European Union. The CHMP positive opinion for Zydelig is based on data from two clinical trials – Study 116 and Study 101-09. Study 116, a pivotal Phase 3 trial, investigated the efficacy and safety of Zydelig in combination with rituximab in patients with previously treated CLL. The Phase 2 101-09 study assessed the efficacy and safety of Zydelig in patients with iNHL who are refractory to rituximab and alkylating agents. Results of Study 116 and Study 101-09 were published in The New England Journal of Medicine in March 2014.
07:17 EDTGILDEMA recommends approval for Gilead, Janssen blood cancer drugs
Subscribe for More Information
06:17 EDTINTCIntel to launch Core M for use in notebook/tablet models in Q4, DigiTimes says
Subscribe for More Information
05:59 EDTINTCStocks with implied volatility below IV index mean; INTC WMB
Stocks with implied volatility below IV index mean; Intel (INTC) 17, Williams (WMB) 22 according to iVolatility.
05:55 EDTGOOGGoogle to buy Twitch for $1B, VentureBeat reports
Google will acquire Twitch, a game livestreaming company, for around $1B, sources confirm to VentureBeat. It is unclear when the deal will be announced or what the exactly purchase price will be, but the sources say YouTube is heading the purchase. Reference Link
July 24, 2014
10:51 EDTGILDStocks with call strike movement; COH GILD
Coach (COH) November 39 call option implied volatility decreased 3% to 30, Gilead (GILD) January 110 call option implied volatility decreased 5% to 30 according to IVolatility.
10:45 EDTEMCEMC downgraded to Buy from Strong Buy at Tigress Financial
Subscribe for More Information
09:36 EDTGILDActive equity options trading on open
Subscribe for More Information
09:10 EDTGILDGilead price target raised to $165 from $123 at BMO Capital
BMO Capital increased its price target on Gilead after the company reported stronger than expected Q2 results. The firm sees significant near-term growth opportunities and long-term sustainability for Gilead's HCV franchise. It keeps an Outperform rating on the shares.
07:55 EDTGILDGilead valuation still appears compelling, says Wells Fargo
After Gilead reported stronger than expected results, Wells Fargo remains upbeat on the outlook for the company's Sovaldi drug. The firm continues to believe that concerns about Sovaldi's pricing will wane into next year. Wells keeps an Outperform rating on the shares.
07:25 EDTGILDGilead price target raised to $109 from $99 at Leerink
Subscribe for More Information
07:25 EDTEMCEMC price target raised to $33 from $30 at Brean Capital
Subscribe for More Information
07:21 EDTGILDGilead removed from short-term buy list at Deutsche Bank
Subscribe for More Information
06:38 EDTGOOGWatchdog says Google evokes memories meant to be omitted, Bloomberg says
Subscribe for More Information
06:01 EDTINTCStocks with implied volatility below IV index mean; INTC SNDK
Subscribe for More Information
05:56 EDTGILDStocks with implied volatility movement; YHOO GILD
Subscribe for More Information
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use